Osteopontin expression in the kidney during unilateral ureteral obstruction

Mineral and Electrolyte Metabolism

Volumn 24, Issue 4, 1998, Pages 227-237

  Kaneto, Hiroyuki ^a   Morrissey, Jerry ^a   McCracken, Ruth ^a   Reyes, Alvaro ^a   Klahr, Saulo ^a,b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

Macrophage chemoattractant; Obstructive nephropathy; Tubulointerstitial fibrosis

Indexed keywords

CHEMOATTRACTANT; ENALAPRIL; MESSENGER RNA; OSTEOPONTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOTAXIS; IMMUNOCYTOCHEMISTRY; KIDNEY DISEASE; KIDNEY FIBROSIS; MACROPHAGE; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; URETER OBSTRUCTION;

ANIMALS; CHEMOTACTIC FACTORS; CHEMOTAXIS; ENALAPRIL; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY CORTEX; KIDNEY GLOMERULUS; KINETICS; MACROPHAGES; OSTEOPONTIN; POLYMERASE CHAIN REACTION; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIALOGLYCOPROTEINS; TISSUE DISTRIBUTION; URETERAL OBSTRUCTION; WHOLE-BODY IRRADIATION;

EID: 0031885201     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057375     Document Type: Article

References (56)

1. Butler W: The nature and significance of osteopontin. Connect Tissue Res 1989;23:123-137.
2. Denhardt DT, Guo X: Osteopontin: A protein with diverse functions. FASEB J 1993;7:1475-1482.
3. Giachelli CM, Pichler R, Lombardi D, Denhardt D, Alpers C, Schwartz S, Johnson R: Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. Kidney Int 1994;45:515-524.
4. Pichler R, Giachelli CM, Lombardi D, Pippin J, Gordon K, Alpers CE, Schwartz SM, Johnson RJ: Tubulointerstitial disease in glomerulonephritis; potential role of osteopontin (uropontin). Am J Pathol 1994;144:915-926.
5. Schreiner GF, Harris KPG, Purkerson ML, Klahr S: Immunological aspects of acute ureteral obstruction: Immune cell infiltrate in the kidney. Kidney Int 1988;34:487-493.
6. Kaneto H, Morrissey J, Reyes AA, McCracken R, Klahr S: Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed kidney of the rat. Kidney Int 1994;45:1637-1647.
7. 1 in experimental hydronephrosis. Am J Physiol 1994; 266:F926-F933.
8. Klahr S, Bander SJ: Obstructive nephropathy, in Massry SG, Glassock RJ (eds): Textbook of Nephrology, ed 2. Orlando, Williams & Wilkins, 1989, vol II, pp 889-909.
9. Rovin B, Harris K, Morrison A, Klahr S, Schreiner G: Renal cortical release of a specific macrophage chemoattractant in response to ureteral obstruction. Lab Invest 1990;63:213-220.
10. Young B, Burdmann E, Alpers C, Eng E, Andoh T, Johnson R, Bennett W, Couser W: Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity (abstract). J Am Soc Nephrol 1993;4: 762.
11. Singh RP, Patarca R, Schwartz J, Singh P, Cantor H: Definition of a specific interaction between the early T lymphocyte activation 1 (eta1) protein and murine macrophages in vitro and its effect upon macrophages in vivo. J Exp Med 1990;171:1931-1942.
12. Diamond JR, Kees-Folts D, Ricarado SD, Pruznak A, Eufemio M: Early and persistent up-regulated expression of renal cortical osteopontin in experimental hydronephrosis. Am J Pathol 1995;146:1455-1466.
13. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S: Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 1995;47:1285-1294.
14. Reyes AA, Lefkowith J, Pippin J, Klahr S: Role of the 5-lipooxygenase pathway in obstructive nephropathy. Kidney Int 1992;41:100-106.
15. 1 mRNA in the obstructed kidney of rats with unilateral ureteral obstruction. Kidney Int 1993;44:313-321.
16. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
17. Miyazaki Y, Setoguchi M, Yoshida S, Higuchi Y, Akizuki S, Yamamoto S: The mouse osteopontin gene; expression in monocytic lineages and complete nucleotide sequence. J Biol Chem 1990;265:14432-14438.
18. Fort P, Marty L, Piechaczyk M, Sabrouty SE, Dani C, Jeanteur P, Blanchard JM: Various rat adult tissue express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acid Res 1985;13:1431-1442.
19. Noda M, Yoon K, Prince CW, Butler WT, Rodan GA: Transcriptional regulation of osteopontin production in rat osteosarcoma cells by type β transforming growth factor. J Biol Chem 1988;263:13916-13921.
20. Morrissey J, Jones J, Olson R: The isolation and characterization of isoprothrombin in the rat. Biochem Biophys Res Commun 1973;54: 1075-1082.
21. Mosier DE: Separation of macrophages on plastic and glass surfaces. Methods Enzymol 1984;108:294-297.
22. 4-specific binding and function in rat polymorphonuclear leukocytes: Absence of a chemotactic response. J Immunol 1985;134:3356-3363.
23. Reyes A, Porras B, Chasalow F, Klahr S: Administration of L-arginine decreases the infiltration of the kidney by macrophages in obstructive nephropathy and puromycin-induced nephrosis. Kidney Int 1994;45:1346-1354.
24. Reyes AA, Karl IE, Yates J, Klahr S: Low plasma and renal tissue levels of L-arginine in rats with obstructive nephropathy. Kidney Int 1994;45:782-787.
25. Pimentel JL Jr, Martinez-Maldonado M, Wilcox JN, Wang S, Luo C: Regulation of reninangiotensin system in unilateral ureteral obstruction. Kidney Int 1993;44:390-400.
26. Oldberg A, Franzen A, Heinegard D: Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 1986;83:8819-8823.
27. Giachelli CM, Bae N, Lombardi D, Majesky M, Schwartz S: Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2ar). Biochem Biophys Res Commun 1991;177:867-873.
28. Kasugai S, Zhang Q, Overall CM, Wrana JL, Butler WT, Sodek J: Differential regulation of the 55 and 44 kDa forms of secreted phosphoprotein 1 (SPP-I, osteopontin) in normal and transformed rat bone cells by osteotropic hormones, growth factors and a tumor promoter. Bone Miner 1991;13:235-250.
29. Laverdure GR, Banerjee D, Chackalaparampil L, Muckerjee BB: Epidermal and transforming growth factors modulate secretion of a 69 kDa phosphoprotein in normal rat kidney fibroblast. FEBS Lett 1987;222:261-265.
30. Brown LF, Berse B, Van De Water L, Papadopoulos-Sergiou A, Perruzzi CA, Manseau EJ, Dvorak HF, Senger DR: Expression and distribution of osteopontin in human tissues: Widespread association with luminal epithelial surfaces. Mol Biol Cell 1992;3:1169-1180.
31. Lopez CA, Hoyer JR, Wilson PD, Waterhouse P, Denhardt DT: Heterogeneity of osteopontin expression among nephrons in mouse kidneys and enhanced expression in sclerotic glomeruli. Lab Invest 1993;69:355-363.
32. Mark MP, Prince CW, Gay S, Austin RL, Butler WT: 44-kDa bone phosphoprotein (osteopontin) antigenicity at ectopic sites in newborn rats: Kidney and nervous tissues. Cell Tissues Res 1988;251:23-30.
33. Nomura S, Wills WJ, Edwards DR, Heath JK, Hogan BLM: Developmental expression of 2ar (osteopontin) and SPARC (osteonectin) RNA as revealed by in situ hybridization. J Cell Biol 1988;106:441-450.
34. Nemir M, DeVouge MW, Mukherjee BB: Normal rat kidney cells secrete both phosphorylated and nonphosphorylated forms of osteopontin showing different physiological properties. J Biol Chem 1989;264:18202-18208.
35. Bogdan C, Paik J, Vodovotz Y, Nathan C: Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-β and interleukin-10. J Biol Chem 1992; 267:23301-23308.
36. Young P, McDonnell P, Dunnington D, Hand A, Laydon J, Lee J: Pyridinyl imidazoles inhibit IL-I and TNF production at the protein level. Agents Actions 1993;39:667-669.
37. Kohri K, Nomura S, Kitamura Y, Nagata T, Yoshioka K, Iguchi M, Yamate T, Umekawa T, Suzuki Y, Sinohara H, Kurita Y: Structure and expression of the mRNA encoding urinary stone protein (osteopontin). J Biol Chem 1993; 268:15180-15184.
38. Somerman MJ, Fisher LW, Foster RA, Sauk JJ: Human bone sialoprotein I and II enhance fibroblast attachment in vitro. Calcif Tissue Int 1988;43:50-53.
39. Yoon K, Buenaga R, Rodan GA: Tissue specificity and developmental expression of rat osteopontin. Biochem Biophys Res Commun 1987;148:1129-1136.
40. Dvergsten J, Manivel J, Correa-Rotter R, Rosenberg M: Expression of clusterin in human renal diseases. Kidney Int 1994;45:828-835.
41. Connor J, Buttyan R, Olsson C, D'Agati V, O'Toole K, Sawczuk I: SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. Kidney Int 1991;39:1098-1103.
42. Schlegel P, Matthews G, Cichon Z, Aulitzky W, Cheng Y, Chen C-L, Saso L, Goldstein M, Janne O, Bardin W, Vaughan E: Clusterin production in the obstructed rabbit kidney: Correlations with loss of renal function. J Am Soc Nephrol 1992;3:1163-1171.
43. Purkerson ML, Klahr S: Prior inhibition of vasoconstriction normalizes GFR in postobstructed kidneys. Kidney Int 1989;35:1306-1314.
44. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM: Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993;92: 1686-1696.
45. Malyankar UM, Almeida M, Johnson RJ, Pichler RH, Giachelli CM: Osteopontin regulation in cultured epithelial cells. Kidney Int 1997;51:1766-1773.
46. Kleinman JG, Brown D, Bonventre JV, Beshensky AM: Distribution of osteopontin in rat kidney: Upregulation in ischemia (abstract). J Am Soc Nephrol 1993;4:611.
47. Truong L, Farhood A, Tasby J, Gillum D: Experimental chronic renal ischemia. Morphologic and immunologic studies. Kidney Int 1992;41:1676-1689.
48. 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 1995;95: 713-724.
49. Springer TA: Adhesion receptors of the immune system. Nature 1990;346:425-434.
50. Roy-Chaudhury P, Hillis G, McDonald S, Simpson JG, Power DA: Importance of the tubulointerstitium in human glomerulonephritis. II. Distribution of integrin chains β1, α1 to 6 and αV. Kidney Int 1997;52:103-110.
51. Weber GF, Ashkar S, Glimcher MJ, Cantor H: Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996;271: 509-512.
52. Günther U: CD44: A multitude of isoforms with diverse functions; in Dunon D, Mackay CR, Imhof BA (eds): Adhesion in Leukocyte Homing and Differentiation. New York, Springer, 1993, pp 47-63.
53. Hwang S-M, Lopez CA, Heck DE, Gardner CR, Laskin DL, Laskin JD, Denhardt DT: Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. J Biol Chem 1994;269:711-715.
54. Hwang S-M, Wilson PD, Laskin JD, Denhardt DT: Age and development-related changes in osteopontin and nitric oxide synthase mRNA levels in human kidney proximal tubule epithelial cells: Contrasting responses to hypoxia and reoxygenation. J Cell Physiol 1994;160:61-68.
55. Morrissey J, McCracken R, Kaneto H, Vehaskari M, Montani D, Klahr S: Location of an inducible nitric oxide synthase mRNA in the normal kidney. Kidney Int 1994;45:998-1005.
56. Kubes P, Suzuki M, Granger D: Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651-4655.